Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 428.72 KB
Add to list
  1. Search results
  2. Consensus on molecular imaging and th...

Consensus on molecular imaging and theranostics in prostate cancer

Stefano Fanti, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, Noel Clarke, Matthias Eiber, Johann De Bono, et al.
(2018) LANCET ONCOLOGY. 19(12). p.E696-E708
Author
Organization
Abstract
Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.
Keywords
POSITRON-EMISSION-TOMOGRAPHY, PLANAR BONE-SCINTIGRAPHY, ESTRO-SIOG GUIDELINES, BIOCHEMICAL RECURRENCE, RADICAL PROSTATECTOMY, F-18-FLUORIDE PET/CT, DIAGNOSIS, METASTASES, SURVIVAL, RADIOTHERAPY

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 428.72 KB

Citation

Please use this url to cite or link to this publication:

MLA
Fanti, Stefano, et al. “Consensus on Molecular Imaging and Theranostics in Prostate Cancer.” LANCET ONCOLOGY, vol. 19, no. 12, 2018, pp. E696–708, doi:10.1016/S1470-2045(18)30604-1.
APA
Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrio, I., … Oyen, W. J. G. (2018). Consensus on molecular imaging and theranostics in prostate cancer. LANCET ONCOLOGY, 19(12), E696–E708. https://doi.org/10.1016/S1470-2045(18)30604-1
Chicago author-date
Fanti, Stefano, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, et al. 2018. “Consensus on Molecular Imaging and Theranostics in Prostate Cancer.” LANCET ONCOLOGY 19 (12): E696–708. https://doi.org/10.1016/S1470-2045(18)30604-1.
Chicago author-date (all authors)
Fanti, Stefano, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, Noel Clarke, Matthias Eiber, Johann De Bono, Karim Fizazi, Silke Gillessen, Sam Gledhill, Uwe Haberkorn, Ken Herrmann, Rodney J. Hicks, Frederic Lecouvet, Rodolfo Montironi, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Jack A. Schalken, Howard I. Scher, Bertrand Tombal, R. Jeroen A. van Moorselaar, Heindrik Van Poppel, Hebert Alberto Vargas, Jochen Walz, Wolfgang A. Weber, Hans-Jurgen Wester, and Wim J. G. Oyen. 2018. “Consensus on Molecular Imaging and Theranostics in Prostate Cancer.” LANCET ONCOLOGY 19 (12): E696–E708. doi:10.1016/S1470-2045(18)30604-1.
Vancouver
1.
Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, et al. Consensus on molecular imaging and theranostics in prostate cancer. LANCET ONCOLOGY. 2018;19(12):E696–708.
IEEE
[1]
S. Fanti et al., “Consensus on molecular imaging and theranostics in prostate cancer,” LANCET ONCOLOGY, vol. 19, no. 12, pp. E696–E708, 2018.
@article{8674317,
  abstract     = {{Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.}},
  author       = {{Fanti, Stefano and Minozzi, Silvia and Antoch, Gerald and Banks, Ian and Briganti, Alberto and Carrio, Ignasi and Chiti, Arturo and Clarke, Noel and Eiber, Matthias and De Bono, Johann and Fizazi, Karim and Gillessen, Silke and Gledhill, Sam and Haberkorn, Uwe and Herrmann, Ken and Hicks, Rodney J. and Lecouvet, Frederic and Montironi, Rodolfo and Ost, Piet and O'Sullivan, Joe M. and Padhani, Anwar R. and Schalken, Jack A. and Scher, Howard I. and Tombal, Bertrand and van Moorselaar, R. Jeroen A. and Van Poppel, Heindrik and Vargas, Hebert Alberto and Walz, Jochen and Weber, Wolfgang A. and Wester, Hans-Jurgen and Oyen, Wim J. G.}},
  issn         = {{1470-2045}},
  journal      = {{LANCET ONCOLOGY}},
  keywords     = {{POSITRON-EMISSION-TOMOGRAPHY,PLANAR BONE-SCINTIGRAPHY,ESTRO-SIOG GUIDELINES,BIOCHEMICAL RECURRENCE,RADICAL PROSTATECTOMY,F-18-FLUORIDE PET/CT,DIAGNOSIS,METASTASES,SURVIVAL,RADIOTHERAPY}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{E696--E708}},
  title        = {{Consensus on molecular imaging and theranostics in prostate cancer}},
  url          = {{http://doi.org/10.1016/S1470-2045(18)30604-1}},
  volume       = {{19}},
  year         = {{2018}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: